Salvianolic Acid B Inhibited PPARγ Expression and Attenuated Weight Gain in Mice with High-Fat Diet-Induced Obesity

Peijian Wang, Shuyu Xu, Wenzhang Li, Fang Wang, Zhen Yang, Licheng Jiang, Qiulin Wang, Mingqing Huang, Peng Zhou

Department of Cardiology, The First Affiliated Hospital, Chengdu Medical College, Chengdu, China, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China

Key Words
Salvianolic acid B • Obesity • Adipose tissue • Peroxisome proliferator-activated receptor gamma • CCAAT/enhancer binding protein α

Abstract
Background/Aims: Obesity contributes to the development of cardiometabolic disorders such as type 2 diabetes, fatty liver disease and cardiovascular disease. Salvianolic acid B (Sal B) is a molecule derived from the root of Salvia miltiorrhiza (Danshen), which is a traditional Chinese medicine that is widely used to treat cardiovascular diseases. However, the role of Sal B in obesity and obesity-related metabolic disorders is unknown. In this study, we aimed to investigate the effects of Sal B on high-fat diet-induced obesity and determine the possible mechanisms involved. Methods: Male C57BL/6J mice fed a high-fat diet for 12 weeks received a supplement of Sal B (100 mg/kg/day) by gavage for a further 8 weeks. These mice were compared to control mice fed an un-supplemented high-fat diet. 3T3-L1 preadipocytes were used in vitro studies. Results: Sal B administration significantly decreased body weight, white adipose tissue weight, adipocyte size and lipid (triglyceride and total cholesterol) levels in obese mice. Eight weeks of Sal B administration also improved the intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT) scores in high-fat diet-induced obese mice. In 3T3-L1 preadipocytes that were cultured in vitro and induced to differentiate, Sal B reduced the accumulation of lipid droplets and lipid content in a dose-dependent manner. Immunoblotting indicated that Sal B decreased peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) expression but increased the expression of GATA binding protein 2 and 3 (GATA 2, GATA 3) both in vivo and in vitro. Conclusion: Our data suggest that Sal B may reduce obesity and obesity-related metabolic disorders by suppressing adipogenesis. The effects of Sal B in adipose tissue may be related to its action on PPARγ, C/EBPα, GATA-2 and GATA-3.

P. Wang and S. Xu contributed equally to this work.

Mingqing Huang or Peijian Wang
Introduction

The prevalence of obesity is increasing worldwide. The reasons for this increase are complex and involve biological, behavioral and environmental factors [1]. Considering that obesity is deeply intertwined with both cardiovascular disease and diabetes, effective interventions are needed to reduce obesity rates on a population-wide basis [2]. Potential strategies for treating obesity include altering neural signals in the brain to regulate appetite, altering nutrient absorption in the gut, and modifying fat storage while promoting fat oxidation in adipose tissue [3]. Adipocyte differentiation plays a major role during the process of fat mass growth; therefore, control of adipogenesis may be a potential strategy for the prevention of obesity [4]. Adipogenesis is a complex process associated with coordinated changes in gene expression, cell morphology and hormone sensitivity [5]. These processes are influenced by several transcription factors, among which peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT enhancer-binding proteins (C/EBPs) have been extensively studied [5]. A cooperative interaction between PPARγ and C/EBPα drives the expression of genes that are necessary for the generation and maintenance of the adipogenic phenotype; these genes induce morphological changes, lipid accumulation, and insulin sensitivity [6].

Salvianolic acid B (Sal B) is a water-soluble compound derived from the root of Salvia miltiorrhiza (Danshen), which is a Chinese medicinal herb. It has been used widely and successfully as a clinical therapy for various cardio-cerebrovascular disturbance-related diseases for hundreds of years in Asian countries [7, 8]. In recent years, in vivo and in vitro experiments have demonstrated that Sal B exerts a wide range of pharmacological effects. Sal B protects rat brains from ischemia and reperfusion injury by targeting the JAK2/STAT3 pathway [9] and inhibiting stromal cell-derived factor-1 alpha-stimulated cell proliferation and migration of vascular smooth muscle cells through suppression of the CXCR4 receptor [10]. Sal B also inhibits low-density lipoprotein oxidation and neointimal hyperplasia in endothelium-denuded hypercholesterolemic rabbits [11] and suppresses the maturation of human monocyte-derived dendritic cells associated with PPARγ [12]. These studies indicated that Sal B exerts protective effects in the cardio-cerebrovascular system. However, the role of Sal B in obesity is unknown.

Here, we used the high-fat diet-induced obese C57BL/6J mouse model and 3T3-L1 preadipocytes to explore the anti-obesity properties of Sal B. Our results indicated that Sal B treatment reduced weight gain, hyperlipidemia and insulin resistance in mice with high-fat diet-induced obesity. We also showed that Sal B suppressed the expression of PPARγ and C/EBPα both in vivo and in vitro. Thus, Sal B may be effective in the treatment of obesity.

Materials and Methods

Animal treatment

Eight-week-old male C57BL/6J mice (Jackson Labs, Bar Harbor, ME) were given a high-fat diet (SLAC Laboratory Animal Co., Ltd., Shanghai, China) for 12 weeks. Sal B (100 mg/kg daily, Sal B group, n=10) or saline (control group, n=10) was then given by oral gavage for an additional 8 weeks. The composition of the high-fat diet was (wt/wt): 32.06% lard, 3.27% soybean oil, 26.17% casein, 16.35% maltodextrin, 9.0% sucrose, 6.54% cellulose, 4.58% AIN-93 minerals, 1.31% AIN-93 vitamins, 0.39% L-cystine and 0.33% choline. All the animals were maintained under controlled temperature (22±2°C) and lighting (lights on at 6:00 AM and off at 6:00 PM) conditions. The investigation conformed to the Guide for the Care and Use of Laboratory Animals that was published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Experimental Animal Ethics Committee of Fujian University of Traditional Chinese Medicine. Sal B was purchased from Shanghai Tauto Biotech Co., Ltd. (Shanghai, China) and was analyzed by high-performance liquid chromatography. The purity of Sal B was greater than 98%.
Intraperitoneal glucose tolerance and insulin tolerance tests

Intraperitoneal glucose tolerance tests (IPGTT) and intraperitoneal insulin tolerance tests (IPITT) were performed as previously described [13]. The IPGTT was performed after an overnight fast (14 h). Glucose (2 g/kg body weight) was administered via injection into the peritoneal cavity, and blood was obtained from the tail at 0, 30, 60 and 120 min after glucose administration. Blood glucose levels were determined using the OneTouch Ultra blood glucose meter (LifeScan, CA, USA). The IPITT was performed using fed mice on a different day. Humulin R (0.75 U/kg body weight) (Eli Lilly and Co., IN, USA) in sterile saline was administered via injection into the peritoneal cavity. Glucose levels in tail blood were determined at 0, 15, 30, 45 and 60 min after insulin injection.

Histological analysis

Adipose tissue was isolated from mice, fixed in 10% formalin, and embedded in paraffin. Sections (10 μm thickness) were obtained and later stained with hematoxylin and eosin (H&E) for the histological examination of adipocytes. Tissue sections were observed with a microscope (Nikon, TE2000) [14].

Analysis of lipids and insulin levels

Heparinized blood was drawn from the abdominal aorta of anesthetized mice. Concentrations of plasma lipids (triglyceride and total cholesterol) and insulin levels were determined using an enzymatic assay according to the manufacturer’s instructions (Applygen Technologies Inc., China). Triglycerides were extracted from adipocytes and measured using an enzymatic colorimetric assay kit according to the manufacturer’s instructions (Applygen Technologies Inc., China).

Culture of 3T3-L1 preadipocytes and stimulation

3T3-L1 preadipocytes were acquired from the China Center for Type Culture Collection (CCTCC, Wuhan, China). The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-BRL, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mmol/L glutamine in an atmosphere of 5% CO₂ at 37°C [15]. Once confluence was reached, the cells were exposed to a pro-differentiation regimen including dexamethasone (1 μM), insulin (5 μg/mL), and isobutylmethylxanthine (0.5 mM). After 2 days, the cells were then maintained in media containing insulin until they were ready for harvest at day 7 [15]. Mature, differentiated 3T3-L1 cells were fixed and stained with the lipophilic dye oil red O (Sigma-Aldrich). Red staining reveals lipid droplets in the cytoplasm, indicating adipocyte differentiation.

Differentiation was also induced in the absence or presence of Sal B (10 nM, 100 nM, 1 μM, 10 μM, and 100 μM). Sal B was continuously present during the cell culture if not otherwise indicated.

Western blot analysis

Immunoblotting for PPARγ, C/EBPα, GATA binding protein 2 (GATA 2), GATA binding protein 3 (GATA 3) and GAPDH was performed as previously described [16]. Primary antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used for white fat tissue and mature 3T3-L1 cells. After incubation with the secondary antibodies for 1 h, the proteins were detected by enhanced chemiluminescence and quantified using a Gel Doc 2000 Imager (Bio-Rad). The immunoblots showed bands of the expected size for PPARγ, C/EBPα, GATA 2, and GATA 3. Each sample was processed three times.

Statistics

The results are expressed as the mean ± SEM. Comparisons between groups were analyzed using one-way analysis of variance with Bonferroni’s multiple comparison post hoc tests or Student’s t test where appropriate. Two-sided P values <0.05 were considered statistically significant.

Results

Sal B reduced weight gain and hyperlipidemia in high-fat diet-induced obese mice

Sal B (100 mg/kg daily) was added after a high-fat diet was administered for 12 weeks. Sal B did not affect the food intake of the mice (Fig. 1A). As shown in Figure 1B and 1C, mice
treated with Sal B for 8 weeks exhibited significantly reduced body weight and circumference despite the continuous administration of a high-fat diet. The weight gain in the high-fat diet-treated group was 41.51±0.93 g, while the weight gain in high fat diet plus Sal B group was 35.01±0.75 g (n=10). After 8 weeks of Sal B administration, the mice were sacrificed and the plasma lipid levels were analyzed. Eight weeks of Sal B administration decreased both the triglyceride (TG) and total cholesterol (TC) levels in high-fat diet-induced obese mice (Fig. 1D and E).

**Sal B reduced the weight of white adipose tissue and adipocyte size in high-fat diet-induced obese mice**

We next investigated the effects of Sal B on white adipose tissue weight and adipocyte size in high-fat diet-induced obese mice. Eight weeks of Sal B treatment reduced the weight of both visceral adipose tissue and subcutaneous adipose tissue (Fig. 2A and B). Histological analysis showed that adipocyte size in both visceral adipose tissue and subcutaneous adipose tissue was smaller in the Sal B group than in the control group fed a high-fat diet (Fig. 2C, D and E).

**Effects of Sal B on glucose metabolism and insulin resistance in high-fat diet-induced obese mice**

It has been demonstrated that obesity, and perhaps central obesity, promotes insulin resistance [17]. To test whether Sal B could improve obesity-induced insulin resistance, we compared fasting glucose levels, the degree of glucose intolerance and insulin sensitivity in the two groups of mice. Fasting glucose and insulin levels were lower in the obese mice treated with Sal B than in the control mice (Fig. 3A and B). IPGTTs and IPITTs revealed that the obese mice were glucose intolerant and insulin resistant. Furthermore, as shown in Figure
3C and 3D, administration of Sal B for 8 weeks not only improved insulin sensitivity but also lowered plasma glucose levels at 30 min, 60 min, 90 min and 120 min after glucose challenge compared to the control mice. These findings indicated that Sal B improved obesity-induced glucose intolerance and insulin sensitivity.

**Sal B suppressed PPARγ-C/EBPα and increased GATA 2/GATA 3 expression in high-fat diet-induced obese mice**

A complex cascade of transcription factors controls adipogenesis. PPARγ and C/EBPα are at the center of this cascade [18]. A recent study showed that Sal B decreased glucocorticoid (GC)-induced adipogenic differentiation via downregulation of PPARγ mRNA expression [19]. To further understand the possible molecular mechanisms underlying the inhibition of adipogenesis by Sal B, we investigated the expression levels of several adipocyte marker proteins in visceral fat tissue by immunoblot. Eight weeks of Sal B administration depressed PPARγ and C/EBPα expression but increased GATA 2 and GATA 3 expression (Fig. 4A-D).

**Sal B inhibited adipogenesis and decreased PPARγ and C/EBPα expression in 3T3-L1 preadipocytes**

Next, we explored whether the effects of Sal B *in vivo* could be observed *in vitro*. 3T3-L1 preadipocytes were cultured and induced to mature in the presence or absence of Sal
Wang et al. : Salvianolic Acid B Attenuated Weight Gain

Cellular Physiology and Biochemistry

B. Sal B reduced the lipid droplets and the lipid content of adipocytes in a dose-dependent manner (Fig. 5A and B). Immunoblotting showed that Sal B (10 μM) decreased PPARγ and C/EBPα expression in mature adipocytes but not in undifferentiated preadipocytes (Fig. 5C and D, Fig. 6A, C and D). Sal B increased GATA 2 and GATA 3 expression in both differentiated preadipocytes and undifferentiated preadipocytes (Fig. 5E and F, Fig. 6B, E and F).

Fig. 3. Salvianolic acid B improved glucose metabolism in high-fat diet-induced obese mice. A: Effect of Sal B on fasting blood glucose in high-fat diet-induced obese mice (n=10). B: Sal B reduces the plasma insulin level of high-fat diet-induced obese mice (n=10). C: IPITT of mice treated with a high-fat diet or HD+Sal B; #P<0.05, ##P<0.01 versus the HD group (n=6). D: IPGTT (2 g/kg) and fasting blood glucose levels in mice treated with or without Sal B for 8 weeks. #P<0.05, ##P<0.01 versus the HD group (n=6). These data are represented as the means ± SEM and were analyzed with Student’s unpaired t-test.

Fig. 4. Effects of salvianolic acid B on the protein expression of PPARγ, C/EBPα, GATA 2, and GATA 3 in obese mice. A-D: Effects of Sal B on the protein expression of PPARγ, C/EBPα, GATA 2, and GATA 3 in high-fat diet-induced obese mice (n=3). Protein expression is shown relative to GAPDH. #P<0.05 versus the HD group (n=3). The data are represented as the mean ± SEM and were analyzed with Student’s unpaired t-test.
Discussion

The major findings of this study are that Sal B significantly reduced body weight and white adipose tissue weight, lowered lipid levels and improved insulin resistance in high-fat diet-induced obese mice. Histological analysis indicated Sal B decreased adipocyte size in white adipose tissue. In mature, differentiated 3T3-L1 cells in vitro, Sal B decreased lipid content and the expression of PPARγ and C/EBPα while increasing GATA 2 and GATA 3 expression. This response was similar to that observed in the adipose tissue of obese mice in vivo.

Increasing evidence indicates that obese individuals have a substantially higher risk of developing many diseases such as type 2 diabetes, hyperlipidemia, and cardiovascular disease [20]. Thus, the search for compounds that can potentially aid in the treatment of obesity has intensified.

Studies have shown that Sal B has wide pharmacological effects such as increasing coronary blood flow, reducing excitability and conductivity of the myocardium, protecting...
Salvianolic Acid B Attenuated Weight Gain

against myocardial ischemia/reperfusion (I/R) injury, improving microcirculation, inhibiting platelet aggregation and thrombosis, preventing atherosclerosis, protecting and improving kidney function, and reducing blood viscosity. Sal B also exhibits antibacterial, anti-inflammatory and antioxidant properties and can protect brain tissue from I/R injury [7]. Previous studies demonstrated that the oral bioavailability of Sal B was 2.3%-3.9% in rats and approximately 1.07% in dogs [21-23]. After oral administration, salvianolic acid B was absorbed quickly with a $T_{\text{max}}$ of approximately 30 min [24]. Pretreatment with rifampicin, a representative inducer of drug-metabolizing enzymes and transporters, can increase the AUC and $C_{\text{max}}$ values and significantly decrease bile clearance values [25]. A recent study showed that Sal B prevented bone loss in glucocorticoid-treated rats through stimulation of osteogenesis and bone marrow angiogenesis and inhibition of adipogenesis. This study indicated that Sal B may have anti-obesity properties [19].

High-fat diet-treated C57BL/6J mice are a well known model of obesity and pre-type 2 diabetes that exhibit elevated blood glucose and impaired glucose tolerance [26]. They do not develop overt diabetes, but they do develop serious insulin resistance [26]. In this study, we first verified that Sal B not only attenuated weight gain but also decreased lipid levels in high-fat diet-induced obese mice.

Because adipocyte differentiation plays a major role in the process of fat mass growth [4], we then explored the effects of Sal B on visceral fat and subcutaneous fat. Our data indicated that Sal B decreased the weight of adipose tissue and the size of adipocytes, as determined by H&E stain. In vitro, we used 3T3-L1 preadipocytes to explore the effects of Sal B on adipogenesis. The mouse-derived 3T3-L1 preadipocyte cell line is widely used for metabolic studies of obesity. Oil red O stain of mature differentiated 3T3-L1 cells indicated that Sal B reduced the accumulation of lipid droplets and decreased lipid content. These results indicated that Sal B may have an important role in the prevention of adipogenesis.

Weight loss is associated with a decrease in insulin concentration and an increase in insulin sensitivity [27]. We investigated whether the effects of Sal B on weight gain would have an impact on high-fat diet-induced insulin resistance. Eight weeks of Sal B administration by
gavage improved obesity-induced insulin sensitivity and glucose intolerance, as measured by the IPITT and IPGTT, respectively.

PPARγ and C/EBPα are key activators of adipogenesis [28]. Recent reports showed that constitutive GATA 2 and GATA 3 expressions suppressed adipocyte differentiation and trapped cells at the preadipocyte stage and that this effect was mediated, at least in part, through the direct suppression of PPARγ, both of which can form protein complexes with C/EBPα [29]. A recent study showed that Sal B stimulated bone marrow stromal cell (BMSC) differentiation into osteoblasts, increased osteoblast activity, and decreased GC-associated adipogenic differentiation by downregulation of PPARγ mRNA expression [19]. We investigated the effects of Sal B on the expression of these proteins in the visceral fat tissue of high-fat diet-induced obese mice. Immunoblotting showed that administration of Sal B decreased the expression of PPARγ and C/EBPα and increased GATA 2 and GATA 3 expression.

PPARγ is a ligand-activated transcription factor and functions as a heterodimer with retinoid X receptor (RXR) [30]. Activation of PPARγ by thiazolidinediones can reduce insulin resistance and hyperglycemia in patients with type 2 diabetes; however, these drugs can also cause weight gain [31]. It has been shown that moderate reduction of PPARγ activity in mice prevented the insulin resistance and obesity induced by a high-fat diet [32]. In this study, PPARγ antagonists decreased TG content in white adipose tissue, skeletal muscle, and liver [32]. These inhibitors potentiated the effects of leptin and increased fatty acid combustion and energy dissipation, thereby ameliorating high-fat diet-induced obesity and insulin resistance [32]. These results indicated that appropriate functional antagonism of PPARγ may be a logical approach for protection against obesity and obesity-related diseases.

Our study indicated that Sal B increased GATA 2 and GATA 3 expression while it suppressed PPARγ and C/EBPα expression. Sal B prevented the differentiation of preadipocytes and reduced weight gain in obese mice. However, the specific mechanisms by which Sal B prevents the differentiation of preadipocytes require further investigation.

In summary, our findings provided the first evidence that Sal B treatment may be an effective therapeutic strategy for attenuating weight gain in obese individuals.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (NO. 81373940), the Specialized Research Fund for the Doctoral Program of Higher Education (NO. 20133519120001) and the Provincial Natural Science Foundation of Fujian (NO. 2012J05152 and 2012Y4005); the Scientific Research Fund of Chengdu Medical College, China (NO.CYZ13-001) and the Scientific Research Fundation of the Education Department of Sichuan Province, China (NO.14ZB0234).

Disclosure Statement

None

References


Wang et al.: Salvianolic Acid B Attenuated Weight Gain


